Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026GlobeNewsWire · 3 days ago
Arcutis Biotherapeutics (NASDAQ:ARQT) Director Howard Welgus Sells 4,728 Shares of Company StockDefense World · 5 days ago
Why Is Arcutis Biotherapeutics Stock Surging Thursday?Benzinga · Oct 15, 2026
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall ClinicalGlobeNewsWire · Oct 9, 2026
Arcutis' ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty AwardGlobeNewsWire · Oct 6, 2026
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rated “Moderate Buy” by Wall Street BrokeragesDefense World · Oct 3, 2026Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | $0.06 | $0.11 | Beat |
| May 6, 2026 | -$0.02 | -$0.09 | Miss |
| Feb 25, 2026 | $0.03 | $0.13 | Beat |
| Oct 28, 2025 | -$0.10 | $0.06 | Beat |
| Aug 6, 2025 | -$0.18 | -$0.13 | Beat |
| May 6, 2025 | -$0.21 | -$0.20 | Beat |